News/ News/ R&D AbbVie adds to neuroscience pipeline with $1bn Syndesi buy Phil Taylor AbbVie, Alzheimer's disease, depression, M&A, neurology, Syndesi Therapeutics 0 Comment Four years after spinning out from Belgium’s UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought Share X AbbVie adds to neuroscience pipeline with $1bn Syndesi buy https://pharmaphorum.com/news/abbvie-adds-to-neuroscience-pipeline-with-1bn-syndesi-buy/